Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2010

View Archived Issues

Vardenafil improves exercise capacity in phase III trial in subjects with PAH

New dual mTOR/PI3K-alpha inhibitor PF-04979064 may advance to clinic as anticancer agent

MEDI-578 has analgesic effects in rat model of inflammatory pain

New partial 5-HT3 receptor agonist described for treatment of IBS

Omecamtiv mecarbil improves left atrial contractility in healthy males

Vaxin and Stabilitech to collaborate in developing anthrax vaccine

Targacept describes new nicotinic acetylcholine receptor modulators

Shire reports highlights of second quarter 2010

Clinical data on sevuparin in healthy adults support evaluation in phase II trial in malaria

Santarus acquires rights to Rhucin and VLA-1-targeted antibody

Tekmira Pharma offers program update

Addex receives grant to support phase II trial of ADX-48621 for Parkinson's dyskinesia

AP-214 reduces development of acute kidney injury in phase II trial

FDA clarifies position on ProAmatine

Ono Pharma and Astellas submit minodronic acid MAA in Japan for osteoporosis

Advinus Therapeutics discovers new molecule for diabetes type 2

Genzyme to sell genetic testing business to LabCorp

Argenta and Genentech expand collaboration to include BioFocus

Cyclacel and FDA agree on a special protocol assessment for phase III sapacitabine trial

Forest Laboratories responds to FDA's complete response letter on roflumilast

XenoPort advances arbaclofen placarbil to phase III for spasticity in MS

Seattle Genetics discontinues lintuzumab development program

Merck & Co. identifies new muscarinic acetylcholine M1 receptor modulators

New CRFR-1 antagonists claimed by Emory University

Enanta Pharmaceuticals discloses novel inhibitors of HCV NS5

Ariad begins phase II trial of ponatinib in chronic myeloid leukemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...